Britain and America have hammered out a key bilateral deal that will guarantee no levies on British drug exports being sold in the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to boost expenditure on pharmaceuticals through the NHS. This pledge guarantees that import taxes on these crucial products will stay at nothing for a period of 36 months.
This deal follows previous warnings to dramatically increase duties on branded pharmaceutical products, with increases discussed reaching 100%.
"This agreement with the Britain strengthens the global environment for innovative medicines and introduces long-overdue balance to transatlantic pharmaceutical trade," an announcement declared.
Economic Significance
Medicines represent one of the the United Kingdom's biggest exports to the United States, which is easily the biggest buyer for major companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months leading up to September, the UK exported drugs worth billions to the US. This figure accounted for nearly one-fifth of British export trade in that period.
"This agreement secures jobs, stimulates funding and paves the way for the UK to become a international leader for medical research," a minister remarked.
Detailed British Pledges
The agreement includes several key changes from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise overall public funding on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be limited at 15%. In the past, refunds topped twenty percent.
Recent Tensions
The deal comes amid a ongoing row between the sector and the British authorities over spending levels and NHS adoption.
This friction were exacerbated by claims that US consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been paused or scrapped, while major expansions have been directed toward projects in the United States.
One official acknowledged that the NHS must spend more on drugs, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the last ten years.
